Related Experiment Videos
Subunit, recombinant and synthetic hepatitis B vaccines
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1985
Summary
Hepatitis B vaccines have evolved from plasma-derived to polypeptide and synthetic peptide forms, offering enhanced safety and precise characterization. Research explores synthetic peptides for well-defined, potent, and cost-effective hepatitis B vaccines.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Hepatitis B surface antigen (HBsAg) particles were historically used for vaccines, with guidelines established by WHO.
- Plasma-derived vaccines demonstrated safety, immunogenicity, and efficacy in clinical trials.
- Polypeptide vaccines offer advantages like precise biochemical characterization and exclusion of viral genetic material.
Purpose of the Study:
- To review the evolution and advantages of different hepatitis B vaccine types.
- To highlight advancements in polypeptide and synthetic peptide vaccine development.
- To discuss the potential of chemically synthesized peptide vaccines.
Main Methods:
- Review of historical guidelines and clinical trial data for plasma-derived vaccines.
- Exploration of recombinant DNA technology for antigen expression (e.g., in yeast).
- Development and testing of chemically synthesized peptides corresponding to HBsAg sequences.
Main Results:
- Plasma-derived vaccines are immunogenic, efficacious, and safe.
- Recombinant DNA technology enables production of HBsAg in various cell systems.
- Chemically synthesized peptides, when linked to adjuvants, elicit antibodies against HBsAg in animals.
Conclusions:
- Polypeptide and synthetic peptide vaccines present significant advantages over traditional methods.
- Chemically synthesized vaccines hold promise for being well-defined, uniform, safe, and cost-effective.
- Further investigation into synthetic peptide vaccines for hepatitis B and other infectious agents is ongoing.